An act relating to pharmacies; amending s. 465.003, F.S.; revising and providing definitions; amending s. 465.004, F.S.; revising the membership of the Board of Pharmacy; amending s. 465.019, F.S.; establishing Class III institutional pharmacies; providing requirements for such pharmacies; conforming provisions to changes made by the act; amending s. 465.0252, F.S.; revising notice requirements to conform to changes made by the act; amending s. 499.003, F.S.; providing and revising definitions; amending s. 499.01, F.S.; authorizing the distribution of medicinal drugs and prepackaged drug products without a specified permit under certain conditions; deleting a provision exempting certain drug repackers from specified permit requirements; providing an effective date.

Be It Enacted by the Legislature of the State of Florida:

Section 1. Subsections (7) and (13) of section 465.003, Florida Statutes, are amended, and subsections (21) and (22) are added to that section, to read:

465.003 Definitions.—As used in this chapter, the term:

(7) "Institutional formulary system" means a method
whereby the medical staff evaluates, appraises, and selects
those medicinal drugs or proprietary preparations which in the
medical staff's clinical judgment are most useful in patient
care, and which are available for dispensing by a practicing
pharmacist in a Class II or Class III institutional pharmacy.

(13) "Practice of the profession of pharmacy" includes
compounding, dispensing, and consulting concerning contents,
therapeutic values, and uses of any medicinal drug; consulting
concerning therapeutic values and interactions of patent or
proprietary preparations, whether pursuant to prescriptions or
in the absence and entirely independent of such prescriptions or
orders; and conducting other pharmaceutical services. For
purposes of this subsection, "other pharmaceutical services"
means the monitoring of the patient's drug therapy and assisting
the patient in the management of his or her drug therapy, and
includes review of the patient's drug therapy and communication
with the patient's prescribing health care provider as licensed
under chapter 458, chapter 459, chapter 461, or chapter 466, or
similar statutory provision in another jurisdiction, or such
provider's agent or such other persons as specifically
authorized by the patient, regarding the drug therapy. However,
nothing in this subsection may be interpreted to permit an
alteration of a prescriber's directions, the diagnosis or
treatment of any disease, the initiation of any drug therapy,
the practice of medicine, or the practice of osteopathic
medicine, unless otherwise permitted by law. "Practice of the profession of pharmacy" also includes any other act, service, operation, research, or transaction incidental to, or forming a part of, any of the foregoing acts, requiring, involving, or employing the science or art of any branch of the pharmaceutical profession, study, or training, and shall expressly permit a pharmacist to transmit information from persons authorized to prescribe medicinal drugs to their patients. The practice of the profession of pharmacy also includes the administration of vaccines to adults pursuant to s. 465.189 and the preparation of prepackaged drug products in facilities holding Class III institutional pharmacy permits.

(21) "Central distribution facility" means a facility under common control with a hospital holding a Class III institutional pharmacy permit that may dispense, distribute, compound, or fill prescriptions for medicinal drugs; prepare prepackaged drug products; and conduct other pharmaceutical services.

(22) "Common control" means the power to direct or cause the direction of the management and policies of a person or an organization, whether by ownership of stock, voting rights, contract, or otherwise.

Section 2. Subsection (2) of section 465.004, Florida Statutes, is amended to read:

465.004 Board of Pharmacy.—
(2) Seven members of the board must be licensed pharmacists who are residents of this state and who have been engaged in the practice of the profession of pharmacy in this state for at least 4 years and, to the extent practicable, represent the various pharmacy practice settings. Of the pharmacist members, two must be currently engaged in the practice of pharmacy in a community pharmacy, two must be currently engaged in the practice of pharmacy in a Class II, institutional pharmacy or a Modified Class II, or Class III institutional pharmacy, and three must be pharmacists licensed in this state irrespective of practice setting. The remaining two members must be residents of the state who have never been licensed as pharmacists and who are in no way connected with the practice of the profession of pharmacy. No person may be appointed as a consumer member who is in any way connected with a drug manufacturer or wholesaler. At least one member of the board must be 60 years of age or older. The Governor shall appoint members to the board in accordance with this subsection as members' terms expire or as a vacancy occurs until the composition of the board complies with the requirements of this subsection.

Section 3. Subsections (4) and (6) of section 465.019, Florida Statutes, are amended, and paragraph (d) is added to subsection (2) of that section, to read:

465.019 Institutional pharmacies; permits.
(2) The following classes of institutional pharmacies are established:

(d)1. "Class III institutional pharmacies" are those institutional pharmacies, including central distribution facilities, affiliated with a hospital that provide the same services that are authorized by a Class II institutional pharmacy permit. Class III institutional pharmacies may also:

   a. Dispense, distribute, compound, and fill prescriptions for medicinal drugs.
   b. Prepare prepackaged drug products.
   c. Conduct other pharmaceutical services for the affiliated hospital and for entities under common control that are each permitted under this chapter to possess medicinal drugs.
   d. Provide the services in sub-subparagraphs a.–c. to an entity under common control which holds an active health care clinic establishment permit as required under s. 499.01(2)(r).

2. A Class III institutional pharmacy shall maintain policies and procedures addressing:
   a. The consultant pharmacist responsible for pharmaceutical services.
   b. Safe practices for the preparation, dispensing, prepackaging, distribution, and transportation of medicinal drugs and prepackaged drug products.
   c. Recordkeeping to monitor the movement, distribution,
and transportation of medicinal drugs and prepackaged drug products.

d. Recordkeeping of pharmacy staff responsible for each step in the preparation, dispensing, prepackaging, transportation, and distribution of medicinal drugs and prepackaged drug products.

e. Medicinal drugs and prepackaged drug products that may not be safely distributed among Class III institutional pharmacies.

(4) Medicinal drugs shall be dispensed in an institutional pharmacy to outpatients only when that institution has secured a community pharmacy permit from the department. However, an individual licensed to prescribe medicinal drugs in this state may dispense up to a 24-hour supply of a medicinal drug to any patient of an emergency department of a hospital that operates a Class II or Class III institutional pharmacy, provided that the physician treating the patient in such hospital's emergency department determines that the medicinal drug is warranted and that community pharmacy services are not readily accessible, geographically or otherwise, to the patient. Such dispensing from the emergency department must be in accordance with the procedures of the hospital. For any such patient for whom a medicinal drug is warranted for a period to exceed 24 hours, an individual licensed to prescribe such drug must dispense a 24-hour supply of such drug to the patient and must provide the
patient with a prescription for such drug for use after the initial 24-hour period. The board may adopt rules necessary to carry out the provisions of this subsection.

(6) In a Class II or Class III institutional pharmacy, an institutional formulary system may be adopted with approval of the medical staff for the purpose of identifying those medicinal drugs, proprietary preparations, biologics, biosimilars, and biosimilar interchangeables that may be dispensed by the pharmacists employed in such institution. A facility with a Class II or Class III institutional pharmacy permit which is operating under the formulary system shall establish policies and procedures for the development of the system in accordance with the joint standards of the American Hospital Association and American Society of Hospital Pharmacists for the utilization of a hospital formulary system, which formulary shall be approved by the medical staff.

Section 4. Subsection (3) of section 465.0252, Florida Statutes, is amended to read:

465.0252 Substitution of interchangeable biosimilar products.—

(3) A pharmacist who practices in a Class II, Modified Class II, or Class III institutional pharmacy shall comply with the notification provisions of paragraph (2)(c) by entering the substitution in the institution's written medical record system or electronic medical record system.
Section 5. Subsection (39) of section 499.003, Florida Statutes, is amended, and paragraphs (w) and (x) are added to subsection (48) of that section, to read:

499.003 Definitions of terms used in this part.—As used in this part, the term:

(39) "Prepackaged drug product" means a drug that originally was in finished packaged form sealed by a manufacturer and that is placed in a properly labeled container by a pharmacy or practitioner authorized to dispense pursuant to chapter 465 for the purpose of dispensing or by a facility holding a Class III institutional pharmacy permit in the establishment in which the prepackaging occurred.

(48) "Wholesale distribution" means the distribution of a prescription drug to a person other than a consumer or patient, or the receipt of a prescription drug by a person other than the consumer or patient, but does not include:

(w) A hospital covered by s. 340B of the Public Health Service Act, 42 U.S.C. s. 256b, that arranges for a prescription drug wholesale distributor to distribute prescription drugs covered under that act directly to a contract pharmacy. Such hospital is exempt from obtaining a restricted prescription drug distributor permit under s. 499.01(2)(h).

(x) The dispensing or distribution of a medicinal drug by a Class III institutional pharmacy pursuant to s. 465.019.
subsection (5) of section 499.01, Florida Statutes, are amended to read:

499.01  Permits.—

(2) The following permits are established:

(b) Prescription drug repackager permit.—A prescription drug repackager permit is required for any person that repackages a prescription drug in this state.

1. A person that operates an establishment permitted as a prescription drug repackager may engage in distribution of prescription drugs repackaged at that establishment and must comply with all of the provisions of this part and the rules adopted under this part that apply to a prescription drug manufacturer.

2. A prescription drug repackager must comply with all appropriate state and federal good manufacturing practices.

3. A prescription drug repackager permit is not required for distributing medicinal drugs or prepackaged drug products between entities under common control which each hold either an active Class III institutional pharmacy permit under chapter 465 or an active health care clinic establishment permit under paragraph (2)(r). For purposes of this subparagraph, the term "common control" has the same meaning as in s. 499.003(48)(a)3.

(h) Restricted prescription drug distributor permit.—

1. A restricted prescription drug distributor permit is required for:
a. Any person located in this state who engages in the
distribution of a prescription drug, which distribution is not
considered "wholesale distribution" under s. 499.003(48)(a).
b. Any person located in this state who engages in the
receipt or distribution of a prescription drug in this state for
the purpose of processing its return or its destruction if such
person is not the person initiating the return, the prescription
drug wholesale supplier of the person initiating the return, or
the manufacturer of the drug.

c. A blood establishment located in this state which
collects blood and blood components only from volunteer donors
as defined in s. 381.06014 or pursuant to an authorized
practitioner's order for medical treatment or therapy and
engages in the wholesale distribution of a prescription drug not
described in s. 499.003(48)(j) to a health care entity. A mobile
blood unit operated by a blood establishment permitted under
this sub-subparagraph is not required to be separately
permitted. The health care entity receiving a prescription drug
distributed under this sub-subparagraph must be licensed as a
closed pharmacy or provide health care services at that
establishment. The blood establishment must operate in
accordance with s. 381.06014 and may distribute only:

(I) Prescription drugs indicated for a bleeding or
clotting disorder or anemia;

(II) Blood-collection containers approved under s. 505 of
the federal act;

   (III) Drugs that are blood derivatives, or a recombinant
or synthetic form of a blood derivative;
   (IV) Prescription drugs that are identified in rules
adopted by the department and that are essential to services
performed or provided by blood establishments and authorized for
distribution by blood establishments under federal law; or
   (V) To the extent authorized by federal law, drugs
necessary to collect blood or blood components from volunteer
blood donors; for blood establishment personnel to perform
therapeutic procedures under the direction and supervision of a
licensed physician; and to diagnose, treat, manage, and prevent
any reaction of a volunteer blood donor or a patient undergoing
a therapeutic procedure performed under the direction and
supervision of a licensed physician,

as long as all of the health care services provided by the blood
establishment are related to its activities as a registered
blood establishment or the health care services consist of
collecting, processing, storing, or administering human
hematopoietic stem cells or progenitor cells or performing
diagnostic testing of specimens if such specimens are tested
together with specimens undergoing routine donor testing. The
blood establishment may purchase and possess the drugs described
in this sub-subparagraph without a health care clinic
establishment permit.

2. Storage, handling, and recordkeeping of these distributions by a person required to be permitted as a restricted prescription drug distributor must be in accordance with the requirements for wholesale distributors under s. 499.0121.

3. A person who applies for a permit as a restricted prescription drug distributor, or for the renewal of such a permit, must provide to the department the information required under s. 499.012.

4. The department may adopt rules regarding the distribution of prescription drugs by hospitals, health care entities, charitable organizations, other persons not involved in wholesale distribution, and blood establishments, which rules are necessary for the protection of the public health, safety, and welfare.

5. A restricted prescription drug distributor permit is not required for distributions between pharmacies that each hold an active permit under chapter 465, have a common ownership, and are operating in a freestanding end-stage renal dialysis clinic, if such distributions are made to meet the immediate emergency medical needs of specifically identified patients and do not occur with such frequency as to amount to the regular and systematic supplying of that drug between the pharmacies. The department shall adopt rules establishing when the distribution
of a prescription drug under this subparagraph amounts to the
regular and systematic supplying of that drug.

6. A restricted prescription drug distributor permit is
not required for distributing medicinal drugs or prepackaged
drug products between entities under common control that each
hold either an active Class III institutional pharmacy permit
under chapter 465 or an active health care clinic establishment
permit under paragraph (2)(r). For purposes of this
subparagraph, the term "common control" has the same meaning as
in s. 499.003(48)(a)3.

(5) A prescription drug repackager permit issued under
this part is not required for a restricted prescription drug
distributor permitholder that is a health care entity to
repackage prescription drugs in this state for its own use or
for distribution to hospitals or other health care entities in
the state for their own use, pursuant to s. 499.003(48)(a)3.,
if:

(a) The prescription drug distributor notifies the
department, in writing, of its intention to engage in
repackaging under this exemption, 30 days before engaging in the
repackaging of prescription drugs at the permitted
establishment;

(b) The prescription drug distributor is under common
control with the hospitals or other health care entities to
which the prescription drug distributor is distributing
prescription drugs. As used in this paragraph, "common control" means the power to direct or cause the direction of the management and policies of a person or an organization, whether by ownership of stock, voting rights, contract, or otherwise;

(c) The prescription drug distributor repackages the prescription drugs in accordance with current state and federal good manufacturing practices; and

(d) The prescription drug distributor labels the prescription drug it repackages in accordance with state and federal laws and rules.

The prescription drug distributor is exempt from the product registration requirements of s. 499.015 with regard to the prescription drugs that it repackages and distributes under this subsection. A prescription drug distributor that repackages and distributes prescription drugs under this subsection to a not-for-profit rural hospital, as defined in s. 395.602, is not required to comply with paragraph (c) or paragraph (d), but must provide to each health care entity for which it repackages, for each prescription drug that is repackaged and distributed, the information required by department rule for labeling prescription drugs. The department shall adopt rules to ensure the safety and integrity of prescription drugs repackaged and distributed under this subsection, including rules regarding prescription drug manufacturing and labeling requirements.
Section 7. This act shall take effect July 1, 2018.